T. Rowe Price Associates’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-320,461
| Closed | -$16.6M | – | 3047 |
|
|
2022
Q3 | $16.6M | Buy |
320,461
+10,332
| +3% | +$427K | ﹤0.01% | 962 |
|
|
2022
Q2 | $7.68M | Sell |
310,129
-55,505
| -15% | -$1.22M | ﹤0.01% | 1358 |
|
|
2022
Q1 | $9.17M | Sell |
365,634
-1,789
| -0.5% | -$50.3K | ﹤0.01% | 1379 |
|
|
2021
Q4 | $13.4M | Sell |
367,423
-9,199
| -2% | -$323K | ﹤0.01% | 1360 |
|
|
2021
Q3 | $6.44M | Sell |
376,622
-68,276
| -15% | -$1.06M | ﹤0.01% | 1478 |
|
|
2021
Q2 | $5.96M | Buy |
444,898
+8,622
| +2% | +$212K | ﹤0.01% | 1482 |
|
|
2021
Q1 | $22.4M | Buy |
436,276
+33,148
| +8% | +$1.99M | ﹤0.01% | 1253 |
|
|
2020
Q4 | $25M | Buy |
403,128
+121,966
| +43% | +$6.98M | ﹤0.01% | 1166 |
|
|
2020
Q3 | $15.4M | Sell |
281,162
-351,795
| -56% | -$18.9M | ﹤0.01% | 1208 |
|
|
2020
Q2 | $36.4M | Buy |
632,957
+464,993
| +277% | +$25.3M | ﹤0.01% | 956 |
|
|
2020
Q1 | $6.75M | Buy |
167,964
+76,364
| +83% | +$3.24M | ﹤0.01% | 1291 |
|
|
2019
Q4 | $3.62M | Buy |
+91,600
| New | +$1.61M | ﹤0.01% | 1458 |
|
|
2018
Q2 | – | Sell |
-460,141
| Closed | -$6.26M | – | 2612 |
|
|
2018
Q1 | $6.26M | Buy |
+460,141
| New | +$4.75M | ﹤0.01% | 1403 |
|
|
2013
Q4 | – | Sell |
-646,800
| Closed | -$3.6M | – | 2521 |
|
|
2013
Q3 | $3.6M | Sell |
646,800
-24,100
| -4% | -$261K | ﹤0.01% | 1469 |
|
|
2013
Q2 | $9.49M | Buy |
+670,900
| New | +$8.69M | ﹤0.01% | 1265 |
|
Other funds holding CCXI
T. Rowe Price Associates's CCXI Position: Q4 2022 in Review
T. Rowe Price Associates sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 320,461 shares — an estimated $16.6M sold.
T. Rowe Price Associates first reported a position in CCXI in Q2 2013 and held it in 15 quarters. The position peaked at $36.4M in Q2 2020. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- T. Rowe Price Associates reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- T. Rowe Price Associates sold 320,461 ChemoCentryx, Inc. shares in Q4 2022, an estimated $16.6M.
- T. Rowe Price Associates first reported a position in ChemoCentryx, Inc. in Q2 2013 and held it in 15 quarters.
- T. Rowe Price Associates's ChemoCentryx, Inc. position peaked at $36.4M in Q2 2020.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on T. Rowe Price Associates's 13F filing for Q4 2022, filed 14 Feb 2023.